The INSM1 gene encodes a transcriptional repressor that is exclusively expressed in neuronal and neuroendocrine tissue during embryonic development that is re-activated in neuroendocrine tumors. Using the 1.7 kbp INSM1 promoter, an adenoviral HSV thymidine kinase gene therapy was tested for the treatment of neuroendocrine tumors. An unforeseen interference on the INSM1 promoter specificity from the adenoviral genome was observed. Attempts were made to protect the INSM1 promoter from the influence of essential adenoviral sequences and to further enhance the tissue specificity of the INSM1 promoter region. Using the chicken b-globin HS4 insulator sequence, we eliminated off-target tissue expression from the Ad-INSM1 promoter-luciferase2 constructs in vivo. In addition, inclusion of two copies of the mouse nicotinic acetylcholine receptor (n(AchR)) neuronal-restrictive silencer element (NRSE) reduced nonspecific activation of the INSM1 promoter both in vitro and in vivo. Further, inclusion of both the HS4 insulator with the n(AchR) 2 Â NRSE modification showed a two log increase in luciferase activity measured from the NCI-H1155 xenograft tumors compared with the original adenovirus construct. The alterations increase the therapeutic potential of adenoviral INSM1 promoter-driven suicide gene therapy for the treatment of a variety of neuroendocrine tumors.
INTRODUCTION
Neuroendocrine forms of cancer are found in both the pediatric and adult population. Neuroendocrine tumors arise in almost every organ and are defined according to the site of origin. 1 Although the sites of tumor formation are diverse, they share a striking number of common molecular features. Owing to the aggressive nature of these forms of cancer, they are difficult to treat. Conventional treatment options such as chemotherapy and radiation can have deleterious side effects especially in pediatric patients. Even with tumors initially sensitive to conventional therapy, when relapsed, become resistant leaving limited treatment options. Therefore, the development of new targeted treatment strategies is necessary especially for aggressive forms of cancer such as small cell lung cancer (SCLC), high-risk neuroblastoma and medulloblastoma.
Adenovirus is the most frequently utilized virus in cancer gene therapy. Adenovirus has many advantages as a choice for gene therapy including the ability to efficiently infect a wide variety of proliferating and non-proliferating cell types, stability, the ability to generate the virus to high titers, the ability to accept a relatively large transgene and the relative ease to manipulate the viral genome. One of the major limiting factors for viral suicide gene therapy is the lack of targeting resulting in liver toxicity. Therefore, to target an effective therapy to the tumor is essential to limit deleterious side effects. Approaches have been made to transcriptionally regulate the expression of therapeutic genes in cancer cells reviewed in references. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] However, interference from the adenoviral sequences can significantly alter the transcriptional control. [13] [14] [15] [16] [17] One proven method to block interference of the adenoviral sequences with tissue-specific or -inducible promoters is to include the chicken b-globin HS4 insulator element. 13, 15 Most targeted therapy takes advantage of the unique characteristics of the tumor. Taking advantage of the shared gene signatures between neuroendocrine tumors, design of a therapy directed to one form can be readily applied to the other neuroendocrine tumors.
The transcription factor, INSM1 was originally identified because of its differential expression in insulinoma cells. 18 Further analysis revealed that INSM1 is expressed during embryonic development in neuronal and neuroendocrine tissues and is silenced in normal adult tissues. Strong re-activation of INSM1 expression is detected in a variety of childhood and adult neuroendocrine tumors such as retinoblastoma, neuroblastoma, medulloblastoma, SCLC, medullary thyroid carcinoma, insulinoma, pheochromocytoma and pituitary tumors. Using a transgenic mouse model, a 1.7 kbp region of the human INSM1 5' upstream regulatory region was fused with the b-galactosidase gene to study the transcriptional activation of promoter. The INSM1 promoter activity was detected in regions overlapping the normal expression pattern of the INSM1 mRNA such as the cerebellum, forebrain, midbrain, hindbrain, spinal cord, thymus, stomach, intestine, pancreas, adrenal gland, pituitary, olfactory bulb and retina in the mouse embryos. 19, 20 In addition, the INSM1 promoter-driven b-galactosidase transgene was silenced during late embryonic development mimicking the developmental regulation observed for the INSM1 mRNA. 19 Use of a nonviral INSM1 promoter-driven suicide gene therapy for SCLC has been demonstrated. 21 We developed an adenoviral INSM1 promoter-driven suicide gene therapy approach for the potential treatment of a variety of INSM1-positive pediatric neuroendocrine tumors. 22 In this study, in vivo imaging of the Ad-INSM1 promoter luciferase2-IRES-HSV-TK suicide gene therapy revealed off-target activity of the INSM1 promoter in mouse pancreas, kidney and lung. Experiments revealed the source of this off-target expression was due to regions within the adenoviral genome. In order to use this approach for targeted therapy, this problem must be overcome.
In this study, different approaches were designed and tested to eliminate the nonspecific activation of the Ad-INSM1 promoter constructs to restore the tissue-selectivity. First, we compared the incorporation of the neuronal-restrictive silencer element (NRSE) from the mouse nicotinic acetylcholine receptor (n(AchR)) or rat superior cervical-ganglion 10 (SCG10) genes, the basic helix loop helix-OB2 octamer-binding promoter (H/O) enhancer from the calcitonin/calcitonin gene-related peptide (CT/CGRP) promoter, or mutagenesis of the TATA-like element in the INSM1 promoter into a canonical TATA box. Only the n(AchR) 2 Â NRSE element in the downstream position relative to the INSM1 promoter region was beneficial both to reduce expression in non-neuronal cell lines and to modestly increase INSM1 promoter activity in the retinoblastoma, neuroblastoma and SCLC cell lines. In addition, the chicken b-globin HS4 insulator sequence was incorporated in various configurations with the adenoviral INSM1 promoter constructs to test whether it could prevent off-target tissue activation of the INSM1 promoter in vivo. One configuration, designated Ad-M3, diminished the non-tumor expression of the transgene, thus restoring the tissue specificity of the INSM1 promoter within the adenoviral backbone. Insulation from the adenoviral sequences coupled with the addition of a NRSE element in the INSM1 promoter-driven reporter constructs showed an overall reduction in normal tissue expression and a two log increase in activity over the unmodified, non-insulated adenoviral constructs in NCI-H1155 tumor xenografts injected intratumoral (IT). Taken together, these studies demonstrate the improvement to the tissue selectivity of the INSM1 promoter and its usefulness in adenoviral cancer gene therapy for the treatment of neuroendocrine tumors.
MATERIALS AND METHODS

Cell culture
The NCI-H69, NCI-H1155, SHP-77, IMR-32, Y79, U87MG, Cos 7, HEK-293 and HepG2 cell lines were obtained from American Type Culture Collections (ATCC, Manassas, VA, USA). Ad-293 cells were purchased from Agilent Technologies (Santa Clara, CA, USA) and were maintained according to ATCC's or Agilent's instructions. All the cells lines were cultured in Royal Parks Memorial Institute (RPMI) 1640 or Dulbecco's modified eagle's media containing 10% fetal bovine serum and 1% penicillin/streptomycin in a 37 1C incubator with 5% CO 2 . All cell culture media was obtained from Mediatech (Manassas, VA, USA) unless otherwise noted.
DNA constructs
Modification to the INSM1 promoter region. In order to functionally test the effect of inclusion of various neuronal-specific DNA elements on the INSM1 promoter activity, all the constructs were compared in the pGL3Basic reporter vector (Promega, Madison, WI, USA). The human INSM1 promoter from nucleotides À 1661 to þ 40 bp was subcloned into the SmaI site of the pGL3 Basic vector as described. 19 To modify the promoter region, two tandem copies of the neuronal-restrictive silencer element (NRSE) derived from either the rat SCG10 or mouse n(AchR) promoter regions were synthesized (Eurofins MWG Operon, Huntsville, AL, USA) and cloned either upstream or downstream with respect to the INSM1 promoter transcription initiation site. All enzymes used for cloning, for example, restriction enzymes, ligase, phosphatase and kinase, were obtained from New England Biolabs (NEB, Ipswitch, MA, USA) unless otherwise noted. In addition, all chemicals were purchased from SigmaAldrich (St Louis, MO, USA). Briefly, the pGL3B-INSM1 promoter constructs were digested with either KpnI (upstream) or BglII (downstream) followed by alkaline phosphatase treatment to prevent vector self-ligation. All synthetic oligonucleotides included a KpnI half-site and a BglII restriction site at both ends of the two tandem copies of the SCG10 or n(AchR) NRSE element for cloning purposes. The oligonucleotide sequence for the SCG10 NRSE element was as follows: 5 0 -cagatct(TTCAGCACCACGGAGAGTGCC) (TTCAGCACCACGGAGAGTGCC)aagcttggtac-3 0 and the reverse complement 5 0 -caagcttaga(GGCACTCTCCGTGGTGCTGAA)(GGCACTCTCCGTGGTGCTGAA) agatctggtac-3 0 . The oligonucleotides generated for the n(AchR) NRSE were the sense 5 0 -cagatct(TTCAGCACCACGGACAGCGCTC)(TTCAGCACCACG GACAGCGCTC)aagcttggtac-3 0 and reverse complement 5 0 -caagctt(GA GCGCTGTCCGTGGTGCTGAA)(GAGCGCTGTCCGTGGTGCTGAA)agatctggtac-3 0 . The oligonucleotides were annealed by heating at 95 1C for 5 min and slow cooled at 1 1C min À 1 in a PCR machine (iCycler; Bio-Rad, Hercules, CA, USA) to generate double-strand products. The ends of the double-strand 2 Â NRSE oligonucleotides were phosphorylated with T 4 polynucleotide kinase in the presence of ATP to facilitate ligation. The oligonucleotides were ligated at 15 1C overnight using T 4 DNA ligase (NEB) into the pGL3B-INSM1 promoter KpnI-treated vector to create the 2 Â NRSE up constructs. Alternatively, the double-strand oligonucleotides were digested with BglII and were ligated at 15 1C overnight with the pGL3B-INSM1 promoter BglII treated vector to generate the 2 Â NRSE down modified INSM1 promoter constructs.
The same procedure was performed to clone the H/O enhancer into the INSM1 promoter luciferase reporter constructs. The DNA element derived from the rat CT/CGRP gene known as the H/O enhancer was synthesized and included KpnI and BglII sites in the linker region with the H/O enhancer sequence, sense oligonucleotides 5 0 -cagatctGGCAGCTGTGCAAATCC Taagcttggtac-3 0 and reverse complement primer 5 0 -caagcttAGGATTTG CACAGCTGCCagatctggtac-3 0 . Finally, the INSM1 promoter region ( À 34 to À 27 bp) spanning the putative TATA-like element was mutated using the Quik Change II Site-Directed Mutagenesis Kit (Agilent Technologies) with the oligonucleotides 5 0 -CTCCCCCCGTATAAAAGGAGCGGCTG-3 0 and the reverse complement to convert the sequence into a consensus TATAbinding site (5 0 -TTAAAAGG to TATAAAAG-3 0 ). The bold nucleotides are the position of the changes that were incorporated into the INSM1 promoter sequence. Briefly, 10 ng of pGL3B-INSM1 promoter plasmid was used as a template in a PCR reaction with the conditions 95 1C for 1 min, followed by 18 cycles of 95 1C for 50 s, 60 1C for 50 s, 68 1C for 6 min 30 s with a final extension at 68 1C for 7 min. The PCR product was digested with DpnI and transformed into XL10 Gold ultra-competent cells. Colonies were screened by sequence analysis (Davis Sequencing, Davis, CA, USA) to confirm that the mutagenesis was successful.
Addition of insulator elements
Constructs incorporating either an insulator and/or NRSE element were generated. The pGL3 luciferase gene was replaced with the luciferase 2 gene from the pGL4.1 vector (Promega) that has been optimized for mammalian expression. The luciferase gene was removed by NcoI/SalI double digestion and replaced with the luciferase 2 (NcoI/SalI) gene from the pGL4.1 vector and subcloned into the INSM1 promoter-2 Â n(AchR) NRSE down containing plasmid to generate the C1 construct. One copy of the 1.2 kbp chicken HS4 b-globin insulator element was digested with KpnI from the pJC13-1 vector (obtained from Dr Gary Felsenfeld, National Institutes of Health, Bethesda, MD, USA), and ligated upstream of the 5 0 end of the INSM1 promoter by digestion of the pShuttle-INSM1 promoterLuc2 vector with KpnI creating the C2 construct lacking an NRSE element. Two tandem copies of the insulator element were cloned into the KpnI site of the pShuttle vector at the 5 0 end of the INSM1 promoter containing the 2 Â n(AchR) NRSE element was designated the M2 construct. The final construct, designated M3, contained both the upstream HS4 insulator and downstream 2 Â n(AchR) NRSE elements. The modified DNA constructs were purified by CsCl gradient and quantitated using a GE nanovue spectrophotometer (Piscataway, NJ, USA).
Transient transfections and reporter gene assays
Twenty-four hours before transient transfection, the cells were seeded at 75 000-100 000 cells per well in a 24-well culture dish. Transient transfections included 200 ng pShuttle INSM1p constructs and 100 ng TKRenilla control plasmid (Promega) for normalization of transfection efficiency. DNA was mixed at a ratio of 1 : 1 with TransFectin Lipid reagent (Bio-Rad) in Optimem (Life Technologies, Grand Island, NY, USA) for 30 min before addition to the wells. All transfections were done in triplicate on at least three separate occasions to confirm the experimental results. Twentyfour hours after transient transfection, the cells were collected, washed Modified INSM1 promoter for neuroendocrine cancer therapy V Akerstrom et al once in 1 Â phosphate-buffered saline, and the cell pellet was resuspended in a final volume of 100 ml of phosphate-buffered saline. Twenty-five microliters of the cell suspension was mixed one to one with Dual Glo luciferase reagent (Promega) and incubated at room temperature for 10 min in a white 96-well plate. The luciferase activity was measured using a TopCount NXT microplate scintillation and luminescence reader (Packard Instrument, Meriden, CT, USA). Twenty-five microliters of Stop and Glo reagent (Promega) was subsequently added to the wells, incubated an additional 10 min, and the plate was re-read to detect Renilla luciferase activity. Data were graphed as the mean of the luciferase activity divided by the Renilla activity. All graphs are shown relative to the control-INSM1p-Luc2 constructs and are set to 100%.
Generation of adenoviral constructs and lysates
In order to generate Ad5 virus for the in vivo studies, the INSM1 promoterLuc2 constructs were transferred into the pShuttle plasmid backbone (Agilent Technologies). The C1, C2, M2 and M3 luciferase 2 constructs were digested with ClaI to remove the various HS4 insulator INSM1 promoter 2 Â NRSE luciferase 2 expression cassette from the pGL3 vector backbone. The ClaI site was filled-in with Klenow enzyme. The pShuttle vector was prepared by digestion with EcoRV and treated with calf intestinal alkaline phosphatase to prevent self-ligation of the vector backbone. Positive clones were verified by restriction digestion and DNA sequence analysis (Davis Sequencing).
To generate adenovirus, the INSM1 promoter-Luc2 constructs were digested with PmeI and treated with calf intestinal alkaline phosphatase. The linearized pShuttle constructs were electroporated into BJ5183 Ad-1 electrocompetent Escherichia coli (E. coli) cells (40 ml, Agilent Technologies) in a 0.2 cm cuvette with a Bio-Rad Gene Pulser II electroporator with the settings 2.5 kV, 200 ohms and 25 mF. Positive clones were re-transformed into XL-10 Gold chemically competent cells (Agilent Technologies) and DNA purified using a Qiagen Midi prep kit (Qiagen, Valencia, CA, USA). Recombinant adenovirus DNA was linearized with PacI and transfected into Ad-293 producer cells with Fugene HD lipid reagent 3 : 1 DNA to lipid ratio (Roche Applied Science, Indianapolis, IN). In all, 10-12 days following the initial transfection, the cells were collected and subjected to four rounds of freeze-thaw lysis to release the viral particles. The viral supernatant was re-infected into Ad-293 cells (human embryonic kidney, Agilent Technologies) for at least two more rounds of amplification. The final round of amplification was done with 40-150 cm tissue culture dishes and the viral lysate was purified on a CsCl gradient. The viral supernatant was dialyzed to remove the CsCl before use. The final viral amplification was titered using the Adeno-X-Rapid Titer Kit (Clontech, Mountain View, CA, USA) and stored at À 70 1C.
Generation of fluorescent-labeled tumor cells
The NCI-H1155 cherry fluorescent cells were generated by infection of H1155 cells with a lentivirus (pNL CMV-vector, Jakob Reiser, Food and Drug Administration, Bethesda, MD, USA) that was engineered to express the cherry fluorescent gene (pmCherry vector, Clontech). The pmCherry vector was first digested with KpnI/XbaI and cloned into pcDNA3vector (Life Technologies). The resulting plasmid was subsequently digested with SnaBI/XhoI and cloned into pNL-CMV-EGFP-WPRE-DU3 by replacing the enhanced green fluorescent protein gene with the pmCherry gene. The lentivirus was generated by using the CalPhos Mammalian Transfection Kit (Clontech) by triple transfection with pCD/NL-BH*DDD (helper plasmid containing HIV-1 Gag/Pol, Tat, Rev DNA) and pLTR-G (the envelope plasmid containing VSV-G glycoprotein DNA) and the pNL-CMV-Cherry-WPRE-DU3 vectors in 293FT cells (Life Technologies). All of the lentiviral vectors were a generous gift from Jakob Reiser (Food and Drug Administration). The virus was collected from the cell supernatant and concentrated by ultracentrifugation. 
In vivo adenovirus biodistribution studies
To verify the specificity of the promoter constructs, 8-week-male athymic Ncr Nu/Nu (NCI, Fredrick, MD, USA) mice were injected with 1 Â 10 6 NCI-H1155 cherry fluorescent tumor cells subcutaneously in the hind flank, and the tumor cells were allowed to grow for 7-10 days. The mice were divided into groups of three, and were injected with 1 Â 10 9 infectious-forming unit (ifu) adenovirus either via IT or intravenous (IV) into the tail vein. One additional IV group was injected with a 1.4 Â 10 10 ifu Ad-C or Ad-M3 adenovirus. Forty-eight hours after virus injection, the mice were imaged on a Kodak In vivo FX multispectral imager (Carestream Health, Woodbridge, CT, USA). Before imaging, the animals were given a single 100 ml, 15 mg ml À 1 intraperitoneal injection of D-luciferin (Biosynth International, Itasca, IL, USA). The animals were immobilized with isoflurane (2-4% by inhalation) for imaging using the program X-ray 2 min, luminescence acquisition for 10 min and fluorescence acquisition for 30 s. Following imaging, the animals were euthanized by CO 2 inhalation and the heart, lungs, liver, kidney, spleen, pancreas and tumors were removed and frozen in 1 to 5 ml of ONEGlo buffer (Promega). The tissues were processed with a tissue homogenizer and centrifuged to clear the homogenate. Total tissue protein was determined with a BCA protein assay kit (Thermo Fisher Scientific, Rockford, IL, USA) and 300 mg total protein per tissue was used to determine luciferase activity. The luciferase activity was measured using a Steady-Glo Luciferase Assay Kit (Promega). For long term biodistribution studies, the animals were given a single 1 Â 10 9 ifu IV injection of virus. The animals were injected with D-luciferin 10 min before image analysis and imaged every 3-5 days for up to 3 months.
In vivo adenovirus tumor efficacy
Eight-week-old male Nu/Nu mice (NCI) were injected with 1 Â 10 6 H1155 cherry tumor cells subcutaneously into the hind flanks and allowed to grow for 10 days. The tumors were injected with 1 Â 10 9 ifu virus particles of the Ad-INSM1p-HSVtk-IRES luciferase 2 construct to simultaneously visualize the location/expression pattern of the virus and to determine the efficacy of the cancer gene therapy. The animals received daily intraperitoneal injections of ganciclovir (cytovene IV Genentech, San Francisco, CA, USA) (50 mg kg À 1 body weight). Elimination of the tumor cells was measured manually by caliper and visually by injection of 100 ml 15 mg ml À 1 D-luciferin followed immediately by image analysis with the Kodak In vivo FX multispectral imager as described above. The animal's tumors were followed for 2 weeks and the tumor growth or regression was measured every other day by image analysis and manually with a caliper.
Liver toxicity study Mice were injected with two different doses of adenovirus 1 Â 10 9 and 1.4 Â 10 10 ifu Ad-C INSM1p-IRES-Luc2 or Ad-M3 Ad-HS4-2 Â NRSE-INSM1p-Luc2 via the tail vein. On day 4 post-virus administration, blood was drawn by cardiac puncture from anesthetized animals. The serum was assayed for both the liver enzymes aspartate transaminase (AST) and alanine transaminase in the clinical laboratory at Children's Hospital, New Orleans, LA, USA.
RESULTS
INSM1 modifications to the INSM1 promoter mRNA is strongly expressed in neuroendocrine tumors such as retinoblastoma, pheochromocytoma, medulloblastoma, neuroblastoma, SCLC, medullary thyroid carcinoma, insulinoma, carcinoid and pituitary tumors. Therefore, we exploited this unique expression pattern for the development of a transcriptionally targeted gene therapy for the treatment of various neuroendocrine tumors. In initial experiments, fusion of the herpes simplex virus thymidine kinase gene with the human INSM1 promoter region demonstrated promoter-specific expression in D283 medulloblastoma, Y79 and IMR-32 cell lines. 22 In this study, we explored ways to potentially increase the activity and specificity of the INSM1 promoter for use in the transcriptionally regulated suicide gene therapy by incorporating other neuronal promoter elements. Two different neuronal elements were selected based on comparison with the tissue distribution pattern known for the INSM1 gene. The first element incorporated was the NRSE that is found in over a hundred different neuronal genes. 23 The NRSE is bound by the neuronal-restrictive silencer factor (NRSF) and functions to repress neuronal gene expression in non-neuronal tissues. 24 Two tandem copies of the NRSE element from either the rat SCG10, 25 or mouse n(AchR) 26, 27 promoter were cloned either upstream or downstream of the INSM1 promoter region. Another modification analyzed was incorporation of the 18 bp neuronal and endocrine-specific enhancer element derived from the rat CT/CGRP gene promoter that is bound by a basic helix loop helix and OB2 octamer-binding protein complex, and termed the H/O enhancer. 28 The CT/CGRP gene is transcribed exclusively in neurons and thyroid C cells, a pattern similar to the INSM1 gene. Finally, the last alteration that was tested changed the non-consensus TATA-like element in the INSM1 promoter to a consensus TATA-binding site to determine if we can increase the transcription rate. Figure 1) . Finally, both the SCG10 and n(AchR) NRSE upstream modifications resulted in a dramatic reduction of INSM1 promoter activity in non-INSM1-expressing cells. For the SCG10 NRSE upstream, there was a measured reduction of 90% in HepG2, 62% in U87MG, 73% in HEK-293 and 56% in Cos-7 ( Figure 1b) . Unfortunately, the SCG10 upstream construct interfered with the INSM1 promoter activity in the INSM1-positive cell lines by 20% in IMR-32, 34% in NCI-H1155, 36% in SHP-77, 38% in Y79 and 49% in D283Med negating any benefit ( Figure 1c) . Next, we analyzed the n(AchR) 2 Â NRSE upstream element in the non-expressing cell lines. Again, this modification resulted in a dramatic decrease in nonspecific activity of the INSM1 promoter by 95% in HepG2, 73% in U87MG and HEK-293, and 34% in Cos-7 ( Figure 1b) . In INSM1-expressing cells, the INSM1 promoter activity was reduced by 35-38% in the IMR-32, Y79, H1155, SHP-77 but strongly repressed by 68% in D283Med (Figure 1b) . Finally, the n(AchR) downstream data were analyzed in the INSM1-negative cell types and resulted in a significant reduction in background promoter activity by 94% in HepG2, 70% in U87MG, 80% in HEK-293 and 64% Cos-7 ( Figure 1b) . Overall, the repressive activity of the n(AchR) 2 Â NRSE in the non-INSM1-expressing cells was superior to the SCG10 2 Â NRSE element. Conversely, the n(AchR) 2 Â NRSE downstream hindered the promoter activity in the D283Med cell line by 62% (Figure 1c) . Although it decreased the promoter activity in the other INSM1-positive cell types it was minimal. The decrease with the n(AchR) downstream was 13% in IMR-32 and Y79, 20% in H1155 and 14% in SHP-77 (Figure 1c) . Except for the D283 medulloblastoma cells, the n(AchR) 2 Â NRSE in the downstream position dramatically reduced nonspecific INSM1 promoter activity in the non-expressing cell lines. However, the overall reduction in nonspecific activity far outweighs the slight decrease to INSM1 promoter activity observed in the expressing cell lines.
Incorporation of insulator elements with or without the n(AchR) 2 Â NRSE downstream element Treatment with the original Ad-INSM1-HSV-TK-IRES-luciferase 2 construct with a single IT injection into H1155 cherry fluorescent non-SCLC (NSCLC)-NE (NCI-H1155) subcutaneous tumors completely eliminated the tumor mass ( Figure 2 ) but a luciferase signal persisted in the absence of tumor cells. Despite the elimination of the E1 region in the replication-defective adenovirus genome, portions of the E1A promoter and enhancer are still left intact. Adenoviral promoters contain multiple cis-acting enhancer elements that function in an orientation and distance to the RNA transcription start site independent manner. 15 The chicken bglobin HS4 insulator elements functionally block enhancer elements when positioned between the promoter and enhancer and have been shown to protect tissue-specific or -inducible promoters in adenovirus backbones. 13, 15, [29] [30] [31] Therefore, we wanted to determine if inclusion of the chicken b-globin HS4 insulator element with our promoter construct could eliminate any potential interference encountered by the adenoviral vector. Extreme efforts were made to incorporate a 1.2 kbp HS4 element both upstream and downstream of the INSM1 promoter-luciferase 2 constructs. However, despite the use of multiple strains of E. coli reported to reduce homologous recombination in bacteria such as the Sure 2 cells (Agilent Technologies), HB101, XL-10Gold (Agilent Technologies) and DH5a, the DNA was unstable and could not be generated. Nonetheless, only constructs with the HS4 insulator either upstream or downstream of the transgene cassette were successfully created. The insulator elements were incorporated with or without the 2 Â NRSE and the constructs and were first tested using transient transfection assays. Four reporter constructs were compared with the original (Figure 3) . The C1 construct contained the 2 Â NRSE but no insulators and is cloned in the pShuttle vector in the antisense orientation with respect to the original construct. The C2 construct was identical to the original INSM1 promoter construct but also contained the 1.2 kbp HS4 insulator upstream of the INSM1 promoter. By virtue of the cloning strategy, the M2 construct contained two tandem copies of the HS4 element upstream of the INSM1 promoter and the 2 Â NRSE element. Finally, the M3 construct contained the 1.2 kbp HS4 element upstream of the INSM1 promoter along with the 2 Â NRSE and is in the reverse orientation in the pShuttle vector ( Figure 3 ). The C2 construct activity is similar to the control in the INSM1-negative cell lines. The C2 activity was lower by 30% in HepG2, no change in U87MG, 14% lower in HEK-293 and 20% lower in Cos-7 (Figure 4a ). The 2 Â NRSE and insulator containing constructs C1, M2 and M3 were reduced significantly in the nonexpressing cell types. In HepG2, the promoter activity was reduced by 70-75%, in U87MG by 40-55%, in HEK-293 by 30-50% and by 60-66% in Cos-7 cells (Figure 4a ). Interestingly, in the INSM1-expressing cell types the C2 construct showed a minimal reduction to the overall activity in the presence of the insulator element 15% in IMR-32 and D283 and 30% in Y79 and H69, and 5% in H1155 (Figure 4b ). Further, in the presence of the 2 Â NRSE without the insulator (C1) promoter activity was unchanged in IMR-32 and D283 cells and was increased by 2.5-fold in Y79 and H69 cells and 1.8-fold in H1155. The only difference between this construct and the one tested in Figure 1 is that the entire transgene construct was cloned in the opposite orientation in the pShuttle reporter vector. The M2 construct containing two tandem copies of the insulator and the 2 Â NRSE element resulted in a 30-40% reduction of promoter activity in the IMR-32 and H69 cells, a 21% decrease in H1155, a 75% reduction in D283 cells and a 1.2-fold increase in Y79 cells (Figure 4b) . Overall, inclusion of two tandem repeats of the insulator element seemed to inhibit the INSM1 promoter activity in INSM1-positive cell lines. Finally, the M3 construct resulted in a modest increase by 1.4-to 1.6-fold in IMR-32 and H69, a 3.4-fold increase in Y79 cells, no change in H1155 and a reduction by 50% in the D283Med cells ( Figure 4b ). As seen in the previous figure, addition of the 2 Â NRSE element reduces background promoter activity in non-INSM1-expressing cell types. In the presence of the insulator element, the 2 Â NRSE actually increased INSM1 promoter activity in the IMR-32, Y79 and H69 cell types when the orientation of the transgene in the pGL3B vector was reversed. As the M2 construct containing two tandem copies of the HS4 insulator diminished INSM1 promoter activity in INSM1-expressing cells, it was eliminated from further studies. . The large gray oval represents the HS4 insulator element, the black diamonds indicate the 2 Â NRSE element, the small black rectangle denotes the SV40 poly-A tail and the black direction arrow designates the start of transcription for the luciferase 2 gene.
Tissue distribution studies with the modified INSM1 promoterluciferase 2 adenovirus constructs Following reporter gene assays, all of the transgenes were recombined into the adenovirus deleted E1 region either in the sense orientation (control and C2) or antisense orientation (C1 and M3) with respect to the E1A enhancer. The control and C2 are identical except for the inclusion of the HS4 insulator element between the E1A enhancer region and the INSM1 promoter. The C1 and M3 constructs both contain the n(AchR) 2 Â NRSE downstream of the INSM1 promoter and are arranged with the SV40 poly A tail adjacent to the E1A enhancer region. In addition, the M3 construct has an insulator element located between the E2 region and INSM1 promoter. In order to monitor the in vivo specificity of the Ad-INSM1 promoter constructs, the luciferase 2 gene was incorporated. Sorted lentiviral cherry fluorescent NCI-H1155 cells were injected into the hind flanks of male nude mice and the tumors were established for 7-10 days. The tumors were directly injected with a single 1 Â 10 9 ifu of each Ad construct. After 48 h, the animals were killed and the liver, lung, pancreas, spleen, kidney and tumor tissues were collected to determine the luciferase activity. In the control adenovirus (Ad-C), the highest signal was detected in the spleen 75 000 relative light unit (RLU) per mg protein followed by the kidney 5500 RLU and lung 4000 RLU (Figure 5a ). The Ad-C1 and Ad-C2 constructs had diminished luciferase activity as compared with the control. The Ad-C1 construct showed a 40-fold reduction in activity in the spleen (Figure 5a ). In contrast, the Ad-C2 construct had 14-fold reduction in the luciferase signal in the spleen, an over 2-fold reduction in the lung and a complete inhibition in the kidney (Figure 5a) . Finally, the Ad-M3 virus revealed a B2.4-fold increase in kidney, a 34-fold reduction in the spleen and a B2.4-fold reduction in the lung (Figure 5a ). The IT tissue data suggest that the 2 Â NRSE element was beneficial to reduce basal expression of the INSM1 promoter constructs in the normal tissue. When comparing the signal generated by the tumor, the Ad-C and Ad-C1 had identical activity in the tumor (Figure 5b) . Interestingly, the Ad-C2 construct was an order of magnitude lower than the Ad-C or Ad-C1 indicating that the adenoviral sequence in fact contributes to the overall observed activity. Surprisingly, the Ad-M3 construct was two orders of magnitude higher in activity in the tumor than any of the other constructs (Figure 5b ). We have simultaneously created an enhanced tumor-specific promoter construct that has increased promoter strength. Next, in NCI-H1155 cherry tumor-bearing animals, the Ad-INSM1 promoter luciferase 2 constructs were injected via the tail vein (IV) and the tissues were collected 48 h later. Again, one of the strongest signals was detected in the spleen. Surprisingly, the highest signal was obtained from the Ad-C1 construct with approximately 180 000 RLU per mg protein, followed by the Ad-C 95 000 RLU and the Ad-C2 45 000 RLU (Figure 5c ). The next highest tissue measured was the Ad-C1 construct in the lung with B110 000 RLU per mg protein. Conversely, all the other constructs were low to undetectable in the lung. Finally, the Ad-C1 construct was high in the kidney 15 000 RLU (Figure 5c ). The Ad-C1 configuration performed well when given IT but not when administered systemically. In contrast, in all the IV tissues, the Ad-M3 construct showed low or no luciferase activity. Analysis of an additional two animals was done to verify the result (lack of signal) with the same outcome. Given the lack of signal in the tumor resulting from systemic injection of the virus, higher doses of virus was given to determine if we could achieve higher levels in the tumor. The original dose, 1 Â 10 9 ifu, and a 14-fold higher dose, 1.4 Â 10 10 ifu was given IV in H1155-cherry tumor-bearing mice. The animals were killed 4 days post-virus delivery and blood was collected. The serum was analyzed for the liver enzymes alanine transaminase and AST. Even at the elevated dose, the Ad-M3 liver enzymes levels remained in the normal range. In contrast, the Ad-C at the higher dose had a slightly elevated AST reading (Supplementary Figure 2) . A luciferase assay performed on the collected tumor tissue revealed 12 000 RLU per mg protein in the Ad-M3 tumors versus 1500 RLU per mg protein or an eightfold increase in luciferase activity (Supplementary Figure 2) . The amount of virus that reaches the tumor via IV injection is limited in systemic delivery. In its current form, our virus does not have any modifications that would target it to the tumor cells for uptake. Therefore, future efforts will be made to transductionally target the virus to the tumor cells.
Biodistribution studies using in vivo imaging
The final test to demonstrate the specificity of the adenovirus constructs was to inject the different viral constructs into nontumor-bearing nude mice. The four viral constructs control, C1, C2 and M3 were injected via the tail vein into 3-5 nude mice per group. The animals were imaged at days 2, 3, 5 and then once a week until the luciferase signal was undetectable. Throughout the entire imaging period, a luciferase signal was not seen in the Ad-C1 group despite having the highest signal from the isolated (Figure 5c ). Initially on day 2, only the spleen and/or kidney area of the Ad-C animals had a signal (Figure 6a) . By day 5, the Ad-C signal was evenly distributed between the lungs and spleen/kidney region (Figure 6a ). Ultimately, the Ad-C animals maintained a strong signal in the lungs from days 9 to 156 (Figure 6c) . Similarly, on day 2 the Ad-C2 animals had a signal that was split evenly between the kidney/ spleen area and the lung (Figure 6b) . By day 5, the Ad-C2 signal was detected exclusively in the lungs where it remained until day 107 (Figure 6e ). The Ad-M3 group, similar to the Ad-C1 group never had any signal either early or late during the screening confirming the specificity that was seen from the tissue assays (Figure 6f) .
DISCUSSION
Previous expression studies have clearly demonstrated that the INSM1 mRNA is regulated in a temporal-and spatial-specific manner. The INSM1 mRNA is detected in the developing mouse embryo in the thymus, thyroid, stomach, intestine, pancreas, retina, brain, spinal cord, adrenal glands and pituitary. 20 Studies from our laboratory demonstrated that a 1.7 kbp region of the INSM1 promoter is sufficient to recapitulate the embryonic expression pattern of the INSM1 gene. 19 Importantly, the promoter is not active in normal adult tissues. Finally, the INSM1 gene is re-activated in most of the neuroendocrine tumors where embryonic INSM1 expression is detected such as retinoblastoma, neuroblastoma, medulloblastoma, medullary thyroid carcinoma, SCLC, carcinoid, pituitary tumor, insulinoma and pheochromocytoma. 18, 32 The regulation of the INSM1 gene creates a unique opportunity to link the INSM1 promoter to a toxic transgene that will specifically target neuroendocrine forms of cancer without affecting the normal surrounding tissues. In a microarray analysis using a panel of SCLC cell lines and normal tissues, INSM1 was identified as a tumor-specific marker for SCLC. 33 Further, quantification using real-time reverse transcriptase-PCR showed a direct correlation between the relative 1.7 kbp INSM1 promoter luciferase activity and the mRNA levels in the SCLC cells. In the same study, transient transfection of the INSM1 promoter-driven HSV-TK construct into the GLC-16 and H69 SCLC cell lines treated with increasing doses of ganciclovir showed an 80% kill rate in vitro. 21 We exploited the spatial and temporal regulatory features of the INSM1 promoter to develop an adenoviral delivered HSV-TK suicide gene therapy for the treatment of pediatric neuroendocrine tumors retinoblastoma, neuroblastoma and medulloblastoma. 22 In our studies, we demonstrated specific activation of the HSV-TK gene in Y79, IMR-32 and D283Med cells. Further, using a D283Med subcutaneous xenograft nude mouse model, a single IT injection of the Ad-INSM1 promoter-driven HSV-TK therapy showed specific antitumor activity. In this study, we incorporated the luciferase 2 reporter gene downstream of the HSV-TK gene using an encephalomyocarditis virus IRES (ECMV internal ribosomal entry site) element for in vivo imaging to monitor the efficacy and specificity of our gene therapy. Using NCI-H1155 NSCLC-NE cells that are permanently labeled with a lentiviral cherry fluorescent protein marker, we established subcutaneous tumors in nude mice. Following a single IT injection with the Ad-INSM1p-HSV-TK-IRES-luciferase 2, the tumor mass was completely eliminated. Unfortunately, in the absence of the tumor mass, a strong luciferase signal was detected in the liver/kidney area of the animals. One possible reason for the signal was some surviving tumor cells invaded through the abdominal wall or the second possibility is that the virus was activated in the normal surrounding tissue. Histological evaluation of the kidney, spleen and pancreas revealed evidence of red fluorescent tumor cells in these organs (data not shown). However, the intensity of the luciferase signal could not be explained by the sparsely scattered tumor cells that are present. We injected naive mice via the tail Figure 5 . Tissue distribution of intratumoral (IT) and intravenous (IV) injected adenovirus HS4 insulator and 2X nicotinic acetylcholine receptor (n(AchR)) neuronal-restrictive silencer element (NRSE) modified INSM1 promoter-luciferase 2 constructs. Subcutaneous NCI-H1155 cherry tumors were established by injection of 1 Â 10 6 cells into the hind flanks of male athymic Nu/Nu mice. In all, 7-10 days following tumor cell injection, the animals were injected IT or IV (via tail vein) with 1 Â 10 9 ifu C, C1, C2 or M3 adenovirus. At 48 h post-injection, the animals were killed and the liver, lung, spleen, pancreas and kidneys were snap frozen in liquid nitrogen in ONEGlo lysis buffer. The tissues were homogenized and assayed for luciferase activity. The NRSE is another excellent candidate to couple with our promoter region. The NRSE is bound by the neuronal-restrictive silencer factor (NRSF). The NRSF is a repressor of a large number of neuronal terminal differentiation genes in non-neuronal tissues as well as neuronal stem cells reviewed in references. 24, [35] [36] [37] [38] [39] [40] Studies with the neuronal n(AchR) b-2 subunit revealed a dual regulatory role of the NRSE. In transgenic mice, the NRSE functioned as either a repressor or enhancer depending on the cellular context in the neurons. 27 In the dynamin 1 gene, a NRSE is found to repress transcription in non-neuronal cells but in adult neurons can activate transcription of dynamin 1 through the same site. 41 In a separate study, the 2 kbp region of the SCG10 promoter was linked with multiple NRSE elements and resulted in enhanced promoter activity in PC12 cells. When the SCG10-NRSE promoter constructs were stereotactically injected directly into regions of the rat brain, it maintained specificity. 42 However, as these promoter constructs are neuronal specific, they would not be suitable for cancer gene therapy because of their high activity in normal cells. In conjunction with the INSM1 promoter, the NRSE element derived from the mouse n(AchR) and SCG10 genes significantly repressed basal promoter activity between 60 and 95% in the non-neuronal cells. This result was extremely encouraging as we want to achieve tightly regulated expression of our toxin gene to minimize potential harmful side effects. Unfortunately, some of the NRSE alterations were also inhibitory to INSM1 promoter activity in the neuroendocrine cell lines. In each case, the NRSE modified promoter activity was reduced significantly in the D283Med cells as compared with the unmodified construct. Although the n(AchR) NRSE down element alone did not enhance the INSM1 activity in the chosen neuroendocrine cells, the dramatic reduction to promoter activity in the nonneuronal cells is desirable. Finally, the n(AchR) NRSE down construct only minimally affected the INSM1 promoter activity in the INSM1-positive cell lines excluding the D283 cells. Another change tested was alteration of the non-consensus TATA-like element into a consensus TATA box. In higher eukaryotes, TATA boxes and initiator (INR) elements direct proper RNA polymerase II transcription initiation in the absence of other core promoter elements. The INSM1 promoter is a GC-rich promoter region that contains multiple potential SP-1-binding sites similar to housekeeping genes that lack a canonical TATA box. The INSM1 Figure 6 . Biodistribution of the Ad-INSM1 promoter-luciferase 2 virus following intravenous injection into non-tumor-bearing nude mice. In order to confirm the specificity of the Ad-INSM1 promoter-luciferase 2 constructs, 1 Â 10 9 ifu C, C1, C2 or M3 virus was injected via the tail vein into non-tumor-bearing male nude mice. Luciferase activity was detected every other day by intraperitoneal injection with D-luciferin (50 mg ml À 1 ) before imaging with the Kodak In vivo FX imager. The animals were imaged using a 2-min X-ray immediately followed by a 10-min luciferase activity measurement every other day for 10 days and then weekly until the signal disappeared around day 156 in the control animals. promoter contains a TATA-like element (TTAAAAGG) located À 34 bp upstream of the experimentally determined transcription start site. 18 The TATA-like box in the INSM1 gene differs from an ideal TATA box and lacks the upstream CAAT box usually associated with TATA containing genes. Therefore, we converted the INSM1 TATA-like site into a consensus TATA box. Unfortunately, there was not a measured benefit in changing the INSM1 TATA element.
Recombinant adenoviruses are an attractive delivery system for gene therapy for several reasons. Adenovirus can readily infect a wide variety of cells both in vitro and in vivo. Owing to the deletion of the E1/E3 region, the virus will not replicate and allows for the incorporation of relatively large transgene cassettes. Despite these advantages, because of the broad tropism of adenovirus, targeting the virus to the appropriate cells is critical to limit harmful side effects. One approach that has been tested is to transcriptionally target the expression of the transgene within the tumor using a tissue-specific promoter, reviewed in Sadeghi and Hitt. 10 For cancer therapy, the telomerase or hTERT promoter has been one of the most widely examined. The hTERT promoter shows tumorspecific activity when used to drive expression of a number of transgenes such as the tumor necrosis factor-related apoptosisinducing ligand, 43 ,44 the herpes simplex virus thymidine kinase 45 or the bacterial nitroreductase genes. 46 Neuroendocrine or neuronal carcinoma-specific promoters have been tested and some examples are the rat calcitonin promoter for treatment of medullary thyroid carcinoma, 47, 48 the gastrin releasing peptide promoter for treatment of SCLC 49 and the midkine promoter for treatment of neuroblastoma. 50, 51 However, the major drawback to these neuronal promoter-enhancer elements is that they are active albeit at a much lower level in normal tissues such as the adrenal gland, lung and brain. In our approach, because of the unique regulatory pattern of the INSM1 promoter, it is inactive in normal tissues but highly active in the neuroendocrine tumors. We created an Ad-INSM1 promoter-driven bicistronic construct connecting the luciferase 2 gene with the HSV-TK gene using an ECMV IRES element to monitor the virus with in vivo imaging. A single IT injection into subcutaneous NCI-H1155 NSCLC-NE tumors completely eliminated all detectable tumor cells. Undesirably, a strong luciferase signal was detected in the liver and kidney region of the animals in the absence of tumor cells. One explanation is that the promoter in the context of the adenovirus is overridden. Specificity of tissue-specific promoters is often hindered by cis-acting viral sequences. 52 Expression can often be restored by incorporating additional polyadenylation sequences or insulator sequences surrounding the expression cassette. 15, 16 One of the most frequently used insulator elements is the chicken b-globin HS4 element. [13] [14] [15] [16] [17] In order to try and restore the tissue specificity of the INSM1 promoter within the adenovirus genome, we chose to flank it with the 1.2 kbp region of the chicken b-globin HS4 insulator element. The insulator from the chicken b-globin locus serves as a boundary between an open chromatin domain and a region of constitutively condensed chromatin. 53 Among adenoviral sequences thought to interfere with heterologous transgene promoters are the inverted terminal repeats, the E1A enhancer, the E2, E4 and pIX promoters. 15 Other laboratories have observed interference from adenovirus elements with tissuespecific promoters. One of the first reports resulted from the nonmuscle-specific expression of LacZ from the ventricular/slow muscle myosin light chain 1 promoter. Intramuscular injection of the virus showed a high level of expression in the connective tissue but little to no activity in the muscle. 54 Insertion of the E1A enhancer region or IX promoter in a plasmid construct adjacent to the myosin light chain 1 promoter inhibited its activity. 54 The Ad-ERBB2 promoter when linked with the HSVTK gene eliminated ERBB2-positive tumors. However, when infected into ERBB2-negative cells, the negative cells were still affected. 16 Similarly, when the metal-inducible promoter was placed in either the forward or reverse orientation in the E1 deleted region, Ad sequences interfered with the promoter activity. To shield the metal-inducible promoter, the chicken HS4 b-globin locus was used 15 and was most effective when the transgene was flanked on both sides by the HS4 elements. Testing was performed in vitro with reporter constructs to determine the most beneficial combination of NRSE and insulator elements before transferring these into adenovirus. Transient transfections revealed that the 2 Â n(AchR) NRSE down containing luciferase constructs maintained the same activity with or without the HS4 element (C1 versus M3). Inclusion of the HS4 element in the absence of the 2 Â NRSE revealed that the construct was identical in activity to the original INSM1 promoter construct (C versus C2). However, the M2 construct containing two tandem copies of the HS4 insulator had a negative effect on the INSM1 promoter activity in vitro in the INSM1-expressing tumor cell lines. Therefore, from these experiments we could conclusively say that a single copy of the HS4 insulator did not interfere or alter the specificity of the INSM1 promoter in vitro. Intriguingly, both the C1 and M3 constructs containing the NRSE element when cloned in the opposite orientation in the pShuttle vector had a higher activity than the control suggesting a negative regulatory region within the pShuttle vector backbone.
Next, all of the constructs except for the M2 were transferred into the E1 deleted region of the adenovirus genome. In the ITinjected groups, the original Ad-C construct displayed a 75-fold increase over background in the spleen of the animals and the next highest activities were in the kidney and lung. The Ad-C1 construct was active only in kidney but at a low level. Therefore, relocation of the INSM1 promoter in the opposite orientation and further away from the E1A enhancer eliminated most of the nonspecific activity. All of the tissues in the Ad-M3 animals had reduced luciferase activity relative to the control except for the kidney, which was increased by B2.3 times control. The Ad-C2 construct like the original had the highest activity in the spleen albeit about one-third less. Overall, the Ad-C1, Ad-C2 and Ad-M3 constructs performed better than the original in IT-injected tissues. When the tumors from the IT animals were analyzed, the Ad-M3 construct containing both the insulator and 2 Â NRSE was two orders of magnitude higher in activity than the original, Ad-C1 or Ad-C2 virus. Comparison of the IV-injected groups showed the strongest signal was detected from the spleen in the Ad-C B95-fold increase, the Ad-C1 B180-fold increase and Ad-C2 with a B45-fold increase over background. The next highest tissues in the Ad-C1 group were the lungs and kidney. Importantly, the IV-injected Ad-M3 animal tissues never registered any signal above background in any of the analyzed tissues. The relocation of the INSM1 promoter further downstream and in the opposite orientation with respect to the E1A enhancer region could not completely eliminate off-target activation of the INSM1 promoter when injected systemically (Ad-C1). However, the Ad-M3 construct with both the HS4 insulator and 2 Â NRSE eliminated all measurable luciferase activity in all tissues from the IV-injected group. Not surprisingly, a limited amount of virus reached the subcutaneous tumors. Next, we administered a higher dose of adenovirus to localize more virus to the tumor mass. We determined the liver toxicity of increasing the IV-injected viruses by measuring the liver enzymes alanine transaminase and AST. In the control group with the higher dose virus, an increase outside the normal AST enzyme range was noted. However, when the virus in the tumor was measured the activity was not improved over the lower dose measurement (Supplementary Figure 2) . Conversely, the Ad-M3 IV-injected tumors had a B8-fold increase in luciferase activity compared with control without an increase in liver toxicity (Supplementary Figure 2) . When Ad5 is injected IV, 95% is bound and rapidly eliminated from the circulation by the Kupffer cells. [55] [56] [57] [58] Therefore, in order for our constructs to be administered systemically, shielding or detargeting would be necessary.
Finally, the adenoviruses were used to perform long-term biodistribution studies in non-tumor-bearing nude mice using in vivo imaging. For these studies, 1 Â 10 9 ifu adenovirus was injected via the tail vein in three to five animals per group. A representative animal is shown from each group. Interestingly, at early time points (days 2 and 3) in the Ad-C and Ad-C2 groups, the luciferase signal is readily detectable in the spleen/pancreas region. Gradually, the luciferase signal was extinguished in the spleen/pancreas area and was found exclusively in the lung. Neither the Ad-C1or Ad-M3 constructs had detectable luciferase activity at any of the time points from days 2 to 156. The Adcontrol virus group maintained signal till day 156 and the Ad-C2 group lost signal between days 102 and 156. Overall, both the Ad-C1 and Ad-M3 performed the best in the animal model. Given the lack of signal detected with the Ad-M3 construct when injected systemically, the absence of strong activity in the spleen from the IT tissue distribution study, and the lack of any activity in the IV tissue distribution study the Ad-M3 construct shows the most promise for further studies. Of note, when compared directly with the other constructs, the Ad-M3 luciferase activity when injected IT was two orders of magnitude higher than the other configurations. The next step in future studies is to incorporate a suicide or toxin gene to be used for the treatment of neuroendocrine forms of cancer such as medulloblastoma, neuroblastoma, SCLC, retinoblastoma, medullary thyroid carcinoma, pituitary tumors and insulinoma. We have previously demonstrated efficacy of the unmodified, non-insulated promoter construct to eliminate the growth of the NCI-H1155 tumor cells. Given that the M3 construct showed two orders of magnitude higher luciferase activity in the H1155 tumor cells, we anticipate the efficacy of the therapy will be significantly improved. Another potential use for the INSM1 promoter constructs is as a diagnostic tool to identify neuroendocrine carcinoma tumors. Owing to the high specificity of the INSM1 promoter and the strong correlation between INSM1 expression and certain neuroendocrine forms of cancer, infection of a tumor biopsy with the Ad-INSM1 promoter-luciferase construct could confirm the diagnosis of a neuroendocrine tumor and simultaneously predict the response the tumor can have to the alternative therapy.
